USPTO Examiner CLARKE TRENT R - Art Unit 1651

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18894673SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSSeptember 2024June 2025Abandon801NoNo
18739955SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSJune 2024January 2025Allow710NoNo
18588987SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024September 2024Allow710YesNo
18588956SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024October 2024Abandon801NoNo
18588930SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2024September 2024Allow710YesNo
18407334DETERGENT COMPOSITIONS COMPRISING BACTERIAL MANNANASESJanuary 2024June 2025Allow1710NoNo
18505438METHODS AND SYSTEMS FOR THE CULTURE OF CELLS AT LIQUID-LIQUID INTERFACESNovember 2023June 2025Abandon1901NoNo
18471478ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTIONSeptember 2023February 2025Allow1710NoNo
18350559AGRICULTURALLY BENEFICIAL MICROBES, MICROBIAL COMPOSITIONS, AND CONSORTIAJuly 2023October 2024Abandon1510NoNo
18134722PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERSApril 2023September 2024Allow1820NoNo
18295428METHOD FOR PRODUCING RETINAL PIGMENT EPITHELIAL CELLSApril 2023October 2024Allow1910NoNo
18295041Device and Method for the Sequestration of Atmospheric Carbon DioxideApril 2023October 2024Abandon1910NoNo
18153974MEDIA FOR STEM CELL PROLIFERATION AND INDUCTIONJanuary 2023October 2023Allow900NoNo
18151095SYSTEM AND METHOD FOR LIQUID FUEL PRODUCTION FROM CARBONACEOUS MATERIALS USING RECYCLED CONDITIONED SYNGASJanuary 2023January 2024Allow1210YesNo
18051969ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTIONNovember 2022September 2023Allow1010YesNo
17935832Medium and Methods For The Storage of Red Blood CellsSeptember 2022November 2024Allow2620NoNo
17743276METHOD FOR PRODUCTION OF A SOIL AMENDMENTMay 2022December 2022Allow710YesNo
17727425Composition and Method for Disrupting Tissue MaterialApril 2022June 2024Abandon2620NoNo
17660051ANTI-CANCER ONCOLYTIC VIRUS COMBINATION THERAPIES AND ELITE RESPONDER SELECTION PLATFORMSApril 2022April 2024Abandon2411NoNo
17712697SERUM-FREE CELL CULTURE MEDIUMApril 2022March 2025Allow3521YesNo
17693500HUMAN FACILITATING CELLSMarch 2022June 2024Abandon2711NoNo
17692579HERBAL COMPOSITION IN POWDER, PILL OR LIQUID FORM FOR SPEEDING UP FRACTURE HEALING AND BONE REGENERATION AND HERBAL FORMULATION IN POWDER, PILL OR LIQUID FORM CONTAINING THE SAMEMarch 2022November 2022Allow810NoNo
17687799USE OF ADHERENT STROMAL CELLS FOR ENHANCING HEMATOPOIESIS IN A SUBJECT IN NEED THEREOFMarch 2022December 2023Abandon2210NoNo
17675502SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINSFebruary 2022February 2024Allow2410NoNo
17636259GROWING PROGRAMMABLE ENZYME-FUNCTIONALIZED AND SENSE-AND-RESPONSE BACTERIAL CELLULOSE LIVING MATERIALS WITH ENGINEERED MICROBIAL CO-CULTURESFebruary 2022November 2023Abandon2101NoNo
17617290NON-TOXIC PROTEASE HAVING IMPROVED PRODUCTIVITYDecember 2021June 2025Allow4211YesNo
17511079MAINTENANCE OF DIFFERENTIATED CELLS WITH LAMININSOctober 2021May 2025Allow4340NoNo
17501775LYOPHILIZED COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUMOctober 2021June 2025Allow4450YesNo
17468765Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral AgentSeptember 2021December 2023Allow2710NoNo
17396530APPARATUS AND METHOD FOR DETECTING CELLS OR PARTICLES IN A FLUID CONTAINERAugust 2021December 2023Allow2820NoNo
17389986USE OF LACTIC ACID BACTERIA FOR PREPARING FERMENTED FOOD PRODUCTS WITH INCREASED NATURAL SWEETNESSJuly 2021December 2024Allow4011YesNo
17370389SERUM-FREE CELL CULTURE MEDIUMJuly 2021December 2023Allow2940YesNo
17364868METHOD AND DEVICE FOR OPENING AN EXTERNAL LAYER STRUCTURE OF CELLS USING LASERJune 2021May 2024Abandon3520NoNo
17349061HERBAL COMPOSITION FOR REDUCING URIC ACID AND THE USE IN REDUCING URIC ACID, BODY FAT, AND BLOOD GLUCOSE THEREOFJune 2021March 2025Allow4530NoNo
17307821SYSTEM AND METHODS FOR IDENTIFYING CANCER CELL LINES HAVING ANTI-GROWTH ACTIVITY AGAINST OTHER CANCER CELL LINESMay 2021November 2023Abandon3010NoNo
17276274INSECT-PATHOGENIC FUNGUS, SPORES, COMPOSITION AND USE OF SAMEMarch 2021June 2025Allow5120NoNo
17275940ANIMAL FEED COMPOSITIONS AND USES THEREOFMarch 2021September 2024Abandon4210NoNo
17178171Reversible method for sustainable human cognitive enhancementFebruary 2021March 2025Abandon4920NoNo
17173327OPTICAL BIO-SENSING DEVICE FOR BIO-MATERIAL ANALYSIS USING UPCONVERSION NANOPARTICLES, AND BIO-MATERIAL QUANTITATIVE ANALYSIS USING THE SAMEFebruary 2021March 2024Allow3710NoNo
17173113Methods for sustainable human cognitive enhancementFebruary 2021March 2025Abandon4920NoNo
17265527CELL-FREE PROTEIN SYNTHESIS METHODFebruary 2021October 2022Abandon2020YesNo
17165192NOVEL VIOLAXANTHIN-OVERPRODUCING STRAIN OF CHLORELLA VULGARIS AND THE METHOD FOR PRODUCING VIOLAXANTHIN USING THE SAMEFebruary 2021April 2023Allow2710NoNo
17264096MEANS AND METHODS FOR CLEAVAGE OF ZEARALENONEJanuary 2021March 2025Allow5011NoNo
17152074IMMOBILIZED PROTEINS AND USE THEREOFJanuary 2021October 2023Abandon3340NoYes
17258783SYSTEM AND METHOD FOR MODULATING STRESS GRANULE ASSEMBLYJanuary 2021September 2024Allow4421NoNo
17143755ARTIFICIAL ORGANELLES FOR ENZYMATIC COFACTOR REDUCTIONJanuary 2021October 2022Allow2101NoNo
17258084PDE3B VARIANTSJanuary 2021August 2024Abandon4310NoNo
17256210Systems and methods for measuring liver enzyme levels in bloodDecember 2020December 2024Allow4720YesYes
17255056ANTI-INFLUENZA VIRUS AGENT FOR SUPPRESSING AGGRAVATION OF INFLUENZADecember 2020October 2024Abandon4620NoNo
17253845Nucleic Acid Binding Domains and Methods of Use ThereofDecember 2020November 2024Allow4720NoNo
17116978ENZYME FORMULATION AND METHOD FOR DEGRADATIONDecember 2020May 2025Abandon5330NoNo
17105925MULTIPARTITE LUCIFERASE PEPTIDES AND POLYPEPTIDESNovember 2020October 2024Allow4721NoNo
17105438FERMENTATION PRODUCTION PROCESS OF PAECILOMYCES HEPIALIS CS-4November 2020March 2024Abandon4020NoNo
16950464COMPOSITIONS AND METHODS FOR PLATELET ENRICHED FIBRIN CONSTRUCTSNovember 2020July 2024Abandon4420NoNo
17096787CELL POTENCY ASSAY FOR THERAPEUTIC POTENTIALNovember 2020September 2023Abandon3401NoNo
17063412OPTICAL-QUALITY SURFACE THAT IMPARTS SPATIAL CONTROL OF MACROPHAGE FUSIONOctober 2020December 2022Allow2610NoNo
17012810BACTERIA FOR DEGRADING ETHYLENE OXIDE AND APPLICATIONS THEREOFSeptember 2020September 2021Allow1320YesNo
17013424NUTRITIONAL SUPPLEMENTS AND METHODS OF NUTRITIONAL SUPPLEMENTATION AFFECTING MICROBIOME METABOLISMSeptember 2020May 2025Abandon5640NoNo
16994356METHODS FOR TREATING DISEASE ASSOCIATED WITH SENESCENCEAugust 2020October 2023Abandon3911NoNo
16942569REDUCING IMMUNOGENICITY TO PEGLOTICASEJuly 2020January 2025Abandon5420NoNo
16961525SOLUBLE ALPHA-KLOTHO PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOFJuly 2020October 2024Allow5111NoNo
16958862METHODS AND SYSTEMS FOR THE CULTURE OF CELLS AT LIQUID-LIQUID INTERFACESJune 2020November 2023Abandon4120NoNo
16955441EXTRACELLULAR MATRIX AND ITS USE FOR REGULATING THE DIFFERENTIATION OF MESENCHYMAL STEM CELLSJune 2020August 2023Abandon3810NoNo
16900970METHODS AND COMPOSITIONS FOR GENERATING EPICARDIUM CELLSJune 2020July 2023Abandon3701NoNo
16890050Microscopy for Rapid Antibiotic Susceptibility Test Using Membrane Fluorescence Staining and Spectral Intensity RatioJune 2020November 2023Abandon4120NoNo
16885999ROBUST DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS INTO ENDOTHELIAL CELLS USING TRANSCRIPTION FACTOR ETV2May 2020October 2024Abandon5321NoYes
16767357HUMANIZED ANTI-MUC1* ANTIBODIES AND DIRECT USE OF CLEAVAGE ENZYMEMay 2020January 2024Abandon4410NoNo
16872061HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPYMay 2020March 2024Abandon4621NoNo
16761313DEVICE AND METHOD FOR THE SEQUESTRATION OF ATMOSPHERIC CARBON DIOXIDEMay 2020April 2023Abandon3511NoNo
16861171BIOLOGICAL TISSUE FOR SURGICAL IMPLANTATIONApril 2020December 2024Abandon5550NoNo
16814892SYSTEM AND METHOD FOR LIQUID FUEL PRODUCTION FROM CARBONACEOUS MATERIALS USING RECYCLED CONDITIONED SYNGASMarch 2020September 2022Allow3031YesNo
16644490WASTE EVACUATION APPARATUS FOR AN AUTOMATED SPECIMEN PREPARATION SYSTEMMarch 2020August 2023Allow4110NoNo
16782372CRYOPROTECTANTS FOR FREEZE DRYING OF LACTIC ACID BACTERIAFebruary 2020December 2022Allow3410NoNo
16634140FUNCTIONAL CORTICAL ORGANOIDS, METHODS OF MAKING, AND USES THEREOFJanuary 2020July 2023Allow4111YesNo
16632229METHOD AND KIT FOR SINGLE CELL PROTEIN EXPRESSION PROFILING OF FLOORPLATE MESENCEPHALIC DOPAMINERGIC PROGENITOR CELLSJanuary 2020January 2024Allow4820YesYes
16742695SERUM-FREE CELL CULTURE MEDIUMJanuary 2020January 2022Allow2431YesNo
16723661Method for removal of harmful sulphurous compounds from gas mixturesDecember 2019May 2023Allow4120NoNo
16712379Implant for Injured Nerve Tissue Prosthetics, Method of Surgical Treatment for Injured Nerve Tissue and Use of Porous PolytetrafluorethyleneDecember 2019January 2023Abandon3710NoNo
16705966METHODS AND COMPOSITIONS FOR PRESERVING TISSUES AND ORGANSDecember 2019June 2024Allow5431NoNo
16618040PURSLANE PROCESSED MATERIAL, METHOD FOR PRODUCING PURSLANE PROCESSED MATERIAL, SUPPLEMENT, MEDICINE, INTESTINAL MUCOSA PROTECTIVE AGENT, AND INTESTINAL REGULATORNovember 2019November 2022Abandon3501NoNo
16692198METHOD OF MANUFACTURING A CULTURE SUPPORT HAVING IMPROVED CELL ADHESIVENESS AND MOBILITYNovember 2019January 2023Abandon3830NoNo
16686437COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMSNovember 2019June 2021Abandon1920YesNo
16667981WHOLE BLOOD VOLUME ANALYZEROctober 2019June 2024Abandon5521YesNo
16657501Nasal Compositions and Method of Use ThereofOctober 2019October 2022Allow3620YesNo
16655506PLASMA DERIVED FROM HUMAN UMBILICAL CORD BLOOD FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERSOctober 2019February 2023Allow4020YesNo
16604633PRINTED TEST STRIPS TO DETERMINE GLUCOSE CONCENTRATION IN AQUEOUS LIQUIDSOctober 2019January 2024Allow5140YesYes
16603213STRAIN IN MICROBACTERIUM AND METHOD FOR PRODUCING PSICOSE USING SAMEOctober 2019August 2023Allow4730NoNo
16500603DETERGENT COMPOSITIONS COMPRISING BACTERIAL MANNANASESOctober 2019December 2023Allow5041YesNo
16583502Methods for Culturing Cells in an Alternating Ionic Magnetic Resonance (AIMR) Multiple-Chambered Culture ApparatusSeptember 2019October 2022Abandon3701NoNo
16579195INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONSSeptember 2019April 2024Abandon5431NoNo
16494728METHOD FOR IRRADIATING MAMMALIAN CELLS WITH ELECTRON BEAMS AND/OR X-RAYSSeptember 2019June 2023Allow4511YesNo
16492972MICROBIOLOGICAL TESTING DEVICE, METHOD FOR PROVISION AND USE OF SUCH A DEVICESeptember 2019December 2022Allow3920NoNo
16490282METHOD FOR THE ENZYMATIC SACCHARIFICATION OF A POLYSACCHARIDEAugust 2019December 2021Abandon2720NoNo
16550720METHOD TO INDUCE SPORE GERMINATION IN FUNGIAugust 2019January 2023Allow4020NoNo
16546424COMPOSITIONS AND METHODS TO PREVENT AND TREAT BIOFILMSAugust 2019July 2020Allow1110NoNo
16512836COMPOSITIONS AND METHODS FOR THE DETECTION OF ZINCJuly 2019May 2022Allow3410YesNo
16501931Method and apparatus to collect, fractionate, and classify airborne particles within specified volumetric regionsJuly 2019March 2021Abandon2020YesNo
16446971METHODS OF TRANSFECTION USING SONOPORATIONJune 2019September 2023Allow5140YesNo
16434131METHOD FOR ASSAYING BIOLOGICAL SAMPLE ON MICROFABRICATED CHIPJune 2019January 2023Abandon4320NoNo
16406862BIOLOGICAL TISSUE FOR SURGICAL IMPLANTATIONMay 2019November 2023Abandon5540NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CLARKE, TRENT R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
12
(80.0%)
Examiner Reversed
3
(20.0%)
Reversal Percentile
29.9%
Lower than average

What This Means

With a 20.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
50
Allowed After Appeal Filing
9
(18.0%)
Not Allowed After Appeal Filing
41
(82.0%)
Filing Benefit Percentile
19.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner CLARKE, TRENT R - Prosecution Strategy Guide

Executive Summary

Examiner CLARKE, TRENT R works in Art Unit 1651 and has examined 414 patent applications in our dataset. With an allowance rate of 37.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.

Allowance Patterns

Examiner CLARKE, TRENT R's allowance rate of 37.7% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by CLARKE, TRENT R receive 2.76 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by CLARKE, TRENT R is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +27.9% benefit to allowance rate for applications examined by CLARKE, TRENT R. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.8% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.2% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 48.3% of appeals filed. This is in the 10% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 68.6% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.5% of allowed cases (in the 59% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.